E.S. BODRYAGINA¹, D.R. AKBEROVA¹, D.D. MUKHAMETOVA¹, D.I. ABDULGANIEVA^1, 2, A.KH. ODINTSOVA²

 ¹Kazan State Medical University of the Ministry of Health of Russia, Kazan

²Republic Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan

 Contact details:

Bodryagina E.S. — PhD (medicine), Assistant of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 237-32-61, e-mail: snezenka@rambler.ru

 The purpose — to reveal the clinical and socio-demographic characteristics of patients with liver and biliary tract diseases depending on nosology; to determine gender differences of the patients.

Material and methods. 292 patients with liver and biliary tract diseases were examined. The patients were on inpatient treatment in the Gastroenterology Department of the Republic Clinical Hospital or observed in the outpatient department.

Results. Among 292 patients, 123 (42,1%) had steatosis, 11 (3,8%) — cholelithiasis, 6 (2,1%) — Gilbert’s syndrome, 152 (52,0%) — autoimmune liver disease (AILD). The prevalence of females was revealed among patients with both hepatic steatosis (67,9%) and AILD (91%). Male patients with non-alcoholic fatty liver disease (NAFLD) had an earlier age of disease onset compared to female patients (47,1 (2,6) vs 53,8 (1,6)). Associated conditions in patients with NAFLD included obesity, cholelithiasis, acid-related diseases, dyslipidemia, impaired motility of the digestive tract, etc.; in patients with AILD — arthralgia, autoimmune thyroiditis, inflammatory bowel disease and other autoinflammatory conditions. The main focus in the management of NAFLD patients was made on non-drug therapy methods, including changes in eating behavior and prevention of hypodynamia, while in patients with AILD drug therapy (immunosuppressants, corticosteroids) played the main role. Patients with NAFLD had a more favorable course of the disease, which made it possible to observe them in the outpatient department, while patients with AILD mostly got inpatient treatment.

Key words: non-alcoholic fatty liver disease, autoimmune liver diseases, gender characteristics, hepatitis.

REFERENCES

1. Drapkina O.M., Gatsolaeva D.S., Ivashkin V.T. Non-alcoholic fatty liver disease in patients with metabolic syndrome. Klinitsist, 2007, no. 6, pp. 46–50 (in Russ.).
2. Balukova E.V., Uspenskiy Yu.P. Non-alcoholic fatty liver disease and metabolic syndrome. Poliklinika, 2014, no. 2, pp. 45–48 (in Russ.).
3. Castro F.A. et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clinical Gastroenterology and Hepatology, 2014, vol. 12 (6), pp. 1038–1045. e7.
4. Ivashkin V.T. et al. Clinical guidelines for the diagnosis and treatment of cholestasis. Ros. zhurn. gastrol. gepatol. koloproktol., 2015, 2013, vol. 25, no. 20, pp. 41–57 (in Russ.).
5. Levitan B.N., Astakhin A.V., Levitan G.B. Tumor necrosis factor and its soluble type II receptors in chronic hepatitis and liver cirrhosis. Eksperimental’naya i klinicheskaya gastroenterologiya, 2017, no. 2 (138) (in Russ.).
6. Vovk E.I. Non-alcoholic fatty liver disease: from scientific advances to clinical algorithms. Meditsinskiy sovet, 2013, no. 10, pp. 46–51 (in Russ.).
7. Topchiy E.A., Opryshko V.V., Filippov A.V., Savin A.A. Sonograficheskie i gendernye osobennosti zabolevaniya gepatobiliarnoy sistemy po dannym ul’trazvukovykh issledovaniy [Sonographic and gender characteristics of the hepatobiliary system disease according to ultrasound examination data]. Nauchnyy forum: Meditsina, biologiya i khimiya: sb. st. po materialam II mezhdunar. nauch.-prakt. konf. no. 2 (2). Moscow: Izd. «MTsNO», 2016. Pp. 43–49.
8. Mack C.L. et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology, 2020, vol. 72 (2), pp. 671–722.
9. Abdollahi M.R., Somi M.H., Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. World journal of gastroenterology: WJG, 2013, vol. 19 (23), pp. 3629.
10. Invernizzi P., Selmi C., Gershwin M. E. Update on primary biliary cirrhosis. Digestive and Liver Disease, 2010, vol. 42 (6), pp. 401–408.
11. Parker D.R., Kingham J.G. Type I autoimmune hepatitis is primarily a disease of later life. QJM: monthly journal of the Association of Physicians, 1997, vol. 90 (4), pp. 289–296.
12. Durazzo M. et al. Gender specific medicine in liver diseases: a point of view. World Journal of Gastroenterology: WJG, 2014, vol. 20 (9), p. 2127.
13. Suzuki A. et al. Associations of gender and a proxy of female menopausal status with histological features of drug‐induced liver injury. Liver International, 2017, vol. 37 (11), pp. 1723–1730.
14. Lohse A.W. et al. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol, 2015, vol. 63 (4), pp. 971–1004.
15. European Association for the Study of the Liver et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of hepatology, 2017, vol. 67 (1), pp. 145–172.
16. Boberg K.M. et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. Journal of hepatology, 2011, vol. 54 (2), pp. 374–385.
17. Ivashkin V.T., Maevskaya M.V., Pavlov Ch.S. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2016, no. 2, pp. 24–42 (in Russ.).
18. Ivashkin V.T., Maevskaya M.V., Pavlov Ch.S. et al. Clinical guidelines of the Russian Society for the Study of the Liver on the management of adult patients with alcoholic liver disease. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2017, no. 27 (6), pp. 20–40 (in Russ.).
19. Abraham C., Cho J.H. Inflammatory bowel disease. The New England Journal of Medicine, 2009, vol. 361, pp. 2066–2078.